Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mahesh Kumar Yadab

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Nutrients|January 28, 2026
Therapeutic Advances of Curcumin and Nanocurcumin in Glioblastoma: Molecular Targets, Bioavailability, and Drug DeliveryMd Ataur Rahman, Mahesh Kumar Yadab, Meser M Ali
Biochemical Pharmacology|August 24, 2025
A modern approach to glioblastoma using temozolomide and nanoparticles carrier drug: a standard care of combination therapy and treatmentMd Ataur Rahman, Mahesh Kumar Yadab, Meser M Ali
Cells|November 27, 2024
Emerging Role of Extracellular pH in Tumor Microenvironment as a Therapeutic Target for Cancer ImmunotherapyMd Ataur Rahman, Mahesh Kumar Yadab, Meser M Ali
Biochemical Pharmacology|September 5, 2025
Overcoming standard-of-care resistance in glioblastoma using nanoparticle-based drug delivery targeting the autophagy pathwayMd Ataur Rahman, Mahesh Kumar Yadab, Meser M Ali
Cancers|February 26, 2025
Progress in Drug Delivery Systems Based on Nanoparticles for Improved Glioblastoma Therapy: Addressing Challenges and Investigating OpportunitiesMd Ataur Rahman, Maroua Jalouli, Mahesh Kumar Yadab, et al.
Biochemical Pharmacology|May 16, 2026
Nanoparticle-Based delivery of proteasome inhibitors for glioblastoma Therapy: Strategies to overcome Blood-Brain barrier and therapeutic resistanceAtaur Rahman, Mahesh Kumar Yadab, Ehsanul Hoque Apu, et al.
Scientific Reports|September 25, 2025
A novel HPβCD-Cu(DDC)<sub>2</sub> delivery system in patient derived orthotopic xenograft targeting MGMT-mediated temozolomide resistance in glioblastomaHamid Suhail, Md Ataur Rahman, Mahesh Kumar Yadab, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Nutrients|January 28, 2026
Therapeutic Advances of Curcumin and Nanocurcumin in Glioblastoma: Molecular Targets, Bioavailability, and Drug DeliveryMd Ataur Rahman, Mahesh Kumar Yadab, Meser M Ali
Biochemical Pharmacology|August 24, 2025
A modern approach to glioblastoma using temozolomide and nanoparticles carrier drug: a standard care of combination therapy and treatmentMd Ataur Rahman, Mahesh Kumar Yadab, Meser M Ali
Cells|November 27, 2024
Emerging Role of Extracellular pH in Tumor Microenvironment as a Therapeutic Target for Cancer ImmunotherapyMd Ataur Rahman, Mahesh Kumar Yadab, Meser M Ali
Biochemical Pharmacology|September 5, 2025
Overcoming standard-of-care resistance in glioblastoma using nanoparticle-based drug delivery targeting the autophagy pathwayMd Ataur Rahman, Mahesh Kumar Yadab, Meser M Ali
Cancers|February 26, 2025
Progress in Drug Delivery Systems Based on Nanoparticles for Improved Glioblastoma Therapy: Addressing Challenges and Investigating OpportunitiesMd Ataur Rahman, Maroua Jalouli, Mahesh Kumar Yadab, et al.
Biochemical Pharmacology|May 16, 2026
Nanoparticle-Based delivery of proteasome inhibitors for glioblastoma Therapy: Strategies to overcome Blood-Brain barrier and therapeutic resistanceAtaur Rahman, Mahesh Kumar Yadab, Ehsanul Hoque Apu, et al.
Scientific Reports|September 25, 2025
A novel HPβCD-Cu(DDC)<sub>2</sub> delivery system in patient derived orthotopic xenograft targeting MGMT-mediated temozolomide resistance in glioblastomaHamid Suhail, Md Ataur Rahman, Mahesh Kumar Yadab, et al.
Pageof 1